Management of chronic hepatitis B in challenging patient populations
- 1 December 2006
- journal article
- Published by Wiley in Liver International
- Vol. 26 (S2) , 38-46
- https://doi.org/10.1111/j.1478-3231.2006.01375.x
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxilGut, 2006
- Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy†Hepatology, 2006
- Switching to adefovir monotherapy after emergence of lamivudine‐resistant mutations in patients with liver cirrhosisJournal of Viral Hepatitis, 2006
- The effect of pegylated interferon-α on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infectionJournal of Hepatology, 2006
- The current management of HBV drug resistanceJournal of Clinical Virology, 2005
- Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine†Hepatology, 2005
- Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationJournal of Hepatology, 2005
- Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 updateLiver International, 2005
- Molecular Virology and the Development of Resistant Mutants: Implications for TherapySeminars in Liver Disease, 2005
- Comparison of Adefovir and Tenofovir in the Treatment of Lamivudine–Resistant Hepatitis B Virus InfectionHepatology, 2004